

Supporting information

A Zwitterionic Salt-Cocrystal: *In-Vitro* Insights from Niraparib Tosylate an Anti-Cancer Drug

Ramesh Reddy Mudda,^a Ramesh Devarapalli,^a Arijit Das,^a L. Pulla Reddy,^a C. Malla Reddy,^{b,c,*} Ramanaiah Chennuru.^{a*}

^aCentre of Excellence Polymorphism, Research and Development, Integrated Product Development (IPD), Cipla Ltd., Bangalore, India.

^bDepartment of Chemistry, Indian Institute of Technology Hyderabad, Hyderabad, Telangana, 502285, India

^cDepartment of Chemical Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur Campus, Mohanpur 741 246, India.

*Corresponding authors

Dr. Ramanaiah Chennuru

Centre of Excellence Polymorphism, Research and Development, Integrated Product Development (IPD), Cipla Ltd., Virgonagar, Bangalore-560 049, Karnataka, India.

Email: Ramanaiah.Chennuru@Cipla.com

Contact No: +91-80-46912332. Fax No: +91-80-28472795.

and

Prof. C. Malla Reddy

Department of Chemistry, Indian Institute of Technology Hyderabad, Hyderabad, Telangana, 502285, India

Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur Campus, Mohanpur 741 246, India.

Phone: (c) +91-9830370458

E-mail: cmreddy@chy.iith.ac.in, cmallareddy@gmail.com

Table of contents:

Figure S1: Powder X-ray Diffraction pattern of NIR.TOS.H₂O (Form I).

Figure S2: Powder X-ray Diffraction pattern of NIR.TOS.PRO.

Figure S3. ¹H-NMR spectra comparison of NIR.TOS.PRO with its starting materials NIR.TOS.H₂O and L-proline.

Table S1: Experimental polymorph screening details.

Table S2: Experimental cocrystal screening details.

Figure S4: PXRD pattern of new polymorph in comparison with NIR.TOS.H₂O.

Figure S5: PXRD pattern of new polymorph in comparison with Form II of Niraparib tosylate.

Figure S6: PXRD pattern of new polymorph in comparison with Form III of Niraparib tosylate.

Figure S7: DSC & TGA overlay of new polymorph of Niraparib tosylate.

Figure S8. ORTEP representation of NIR.TOS.H₂O.

Figure S9. ORTEP representation of NIR.TOS.PRO.

Figure S10. Experimental and simulated PXRD patterns of NIR.TOS.PRO with one-to one correspondence.

Figure S11: Powder X-ray diffraction patterns of NIR.TOS.PRO in pH 1.2, 4.5 and 6.8 buffers.

Figure S12: Overlay of powder X-ray diffraction patterns of stability samples of NIR.TOS.PRO in comparison with the input.

Table S3: Torsion angles that are majorly deviated in NIR.TOS.H₂O and NIR.TOS.PRO.

Table S4: Hydrogen bond parameters of NIR.TOS.H₂O and NIR.TOS.PRO.




Figure S1: Powder X-ray Diffraction pattern of NIR.TOS.H₂O (Form I).




Figure S2: Powder X-ray Diffraction pattern of NIR.TOS.PRO (Zwitterionic salt-cocrystal).




Figure S3. ¹H-NMR spectra comparison of NIR.TOS.PRO with its starting materials NIR.TOS.H₂O and L-proline.

Table S1: Experimental polymorph screening details.

Slurry crystallization				
S. No.	Input Form	Solvent	Temp. (°C)	Result
1	Amorphous	1,2-Dimethoxy ethane	45-50	Form I
2	Form I	1,2-Dimethoxyethane	45-50	Form I
3	Amorphous	1,2-Propanediol	0-5	Form I
4	Amorphous	1,4-Dioxane	0-5	Form I
5	Form I	1,4-Dioxane	25-30	Form I
6	Form I	1,4-Dioxane	45-50	Form I
7	Form I	2,2,2-Trifluoroethanol	35-40	Solid material not isolated
8	Amorphous	2-Butanol	35-40	Form I
9	Form I	2-Butanol	60-65	Form I

10	Amorphous	2-Methoxy ethanol	0-5	Form I
11	Form I	2-Methoxyethanol	45-50	Form I
12	Amorphous	2-Methyl Tetrahydrofuran	0-5	Form I
13	Form I	2-Methyl Tetrahydrofuran	45-50	Form I
14	Form I	2-Pentanol	35-40	Form I
15	Form I	Acetic Acid	25-30	Form I
16	Form I	Acetone + water	25-30	Form I
17	Form I	Acetone + water	70-75	Form I
18	Amorphous	Acetonitrile	25-30	Form I
19	Amorphous	Acetonitrile	65-70	Form I
20	Form I	Acetonitrile	35-40	Form I
21	Form I	Acetonitrile	70-75	Form I
22	Form I	Acetonitrile + 2-butanol	70-75	Form I
23	Form I	Acetonitrile + 2-butanol + Dimethyl sulfoxide	70-75	Form I
24	Amorphous	Anisole	0-5	Form I
25	Form I	Benzyl alcohol	35-40	Solid material not isolated
26	Form I	Benzyl alcohol	-5 to -10	Form I
27	Amorphous	Chloroform	0-5	Form I
28	Amorphous	Dichloromethane	0-5	Form I
29	Amorphous	Dichloromethane	25-30	Form I
30	Amorphous	Diethyl ether	10-15	Form I
31	Amorphous	Diethyl ether	-5 to -20	Form I
32	Form I	Diethylene glycol	35-40	Solid material not isolated
33	Amorphous	Di isopropyl ether	0-5	Form I
34	Amorphous	Di isopropyl ether	25-30	Form I
35	Amorphous	Dimethoxymethane	0-5	Form I
36	Form I	Dimethoxymethane	25-30	Form I
37	Form I	Ethanol	0-5	Form I
38	Form I	Ethanol	35-40	Form I
39	Amorphous	Ethanol + 1,4-Dioxane	25-30	Form I
40	Form I	Ethanol + water	50-55	Form I
41	Amorphous	Ethylene glycol mono propyl ether	0-5	Form I
42	Form I	Formic Acid	25-30	Form I
43	Form I	Glycerol	35-40	Form I
44	Amorphous	Heptane	0-5	Form I
45	Amorphous	Heptane	25-30	Form I
46	Amorphous	Heptane	65-70	Form I
47	Amorphous	Heptane + Acetonitrile	25-30	Form I
48	Form I	Heptane + Acetonitrile	25-30	Form I
49	Amorphous	Heptane + Acetonitrile	55-60	Form I

50	Form I	Hexanoic acid	35-40	Form I
51	Amorphous	Isobutyl acetate	25-30	Form I
52	Form I	Isobutyl acetate	55-60	Form I
53	Form I	Isopropanol	25-30	Form I
54	Form I	Isopropanol	55-60	Form I
55	Form I	Methanol	45-50	Form I
56	Amorphous	Methanol	-5-0	Form I
57	Amorphous	Petroleum ether	25-30	Form I
58	Amorphous	Petroleum ether	-5 to -10	Form I
59	Amorphous	Petroleum ether + Acetonitrile	25-30	Form I
60	Amorphous	Petroleum ether + Acetonitrile	-5 to -10	Form I
61	Amorphous	Petroleum ether + Ethyl acetate	25	Form I
62	Amorphous	Petroleum ether + Heptane	25-30	Form I
63	Form I	pH 4.5 buffer	25-30	Form I
64	Amorphous	pH 4.5 buffer	25-30	Form I
65	Form I	pH 6.8 buffer	25-30	Form I
66	Form I	Sulfolane	35-40	Form I
67	Form I	Xylene	95-100	Form I

Recrystallization

S. No.	Input Form	Solvent	Temp. (°C)	Result
1	Form I	Dimethyl formamide	0-5	Form I
2	Form I	Dimethyl acetamide	0-5	Form I
3	Form I	Dimethyl sulfoxide	0-5	Form I
4	Form I	Methanol	-20 to -25	Form I
5	Form I	Ethanol	-20 to -25	Form I
6	Form I	Methanol + Ethanol	-20 to -25	Form I
7	Form I	Methanol + DMSO	0-5	Form I
8	Form I	2-Methoxy ethanol	-20 to -25	Form I
9	Form I	2-Ethoxy ethanol	-20 to -25	Form I
10	Form I	N-Methyl pyrrolidine	0-5	Form I
10	Form I	Acetic acid	-20 to -25	Form I
11	Form I	Formic acid	-20 to -25	Solid material not isolated

Normal anti-solvent addition

S. No.	Input Form	Solvent	Anti-solvent	Temp. (°C)	Result
1	Form I	Acetic acid	n-Heptane	40-45	Form I
2	Form I	Acetic Acid	n-Heptane	-10 to -15	Form I
3	Form I	Acetic acid + Ethanol	Methyl tertiary butyl ether	25-30	Form I
4	Amorphous	Benzyl alcohol	Dichloromethane + Ethyl acetate	0-5	Form I
5	Form I	Dimethyl sulfoxide	Acetone	0-5	Form I

6	Form I	Dimethyl sulfoxide + Ethanol	Methyl tertiary butyl ether	-5 to -10	Form I
7	Form I	Dimethyl sulfoxide + Methanol	Methyl tertiary butyl ether	25-30	Form I
8	Amorphous	Formic acid	Acetone + Methyl tertiary butyl ether	25-30	Form I
9	Form I	Formic acid	Hexane + Methyl tertiary butyl ether	70-75	Form I
10	Form I	N-Methyl pyrrolidine	Acetone	0-5	Form I
11	Form I	Ethanol	Acetone	0-5	Form I
12	Form I	N-Methyl pyrrolidine + Methanol	Methyl tertiary butyl ether	25-30	Form I
13	Form I	Trichloroacetic acid	Heptane + Methyl tertiary butyl ether	70-75	Form I
14	Form I	Trichloroacetic acid	Methyl tertiary butyl ether	70-75	Form I
15	Form I	Trifluoroethanol	Methyl tertiary butyl ether	-5 to -10	Form I
16	Form I	Methanol	Methyl tertiary butyl ether	25-30	Form I
17	Form I	Methanol	Diethyl ether	25-30	Form I
18	Form I	Trifluoroethanol + Methanol	Methyl tertiary butyl ether	25-30	Form I

Reverse antisolvent addition

S. No.	Input Form	Anti-solvent	Solvent	Temp. (°C)	Result
1	Form I	1,4-Dioxane	Acetic acid	-10 to -15	Form I
2	Form I	1,4-Dioxane	Dimethyl acetamide	-10 to -20	Form I
3	Form I	1,4-dioxane + Chloroform	Formamide	65-70	Form I
4	Form I	Chloroform	Dimethyl acetamide	65-70	Form I
5	Form I	Chloroform + Methyl tertiary butyl ether	Dimethyl acetamide	65-70	Form I
6	Form I	Dichloromethane	Dimethyl sulfoxide	-15 to -20	Form I
7	Form I	Dichloromethane + acetonitrile	N-Methyl pyrrolidine	50-55	Form I
8	Form I	Dichloromethane + Acetonitrile	Formamide	50-55	Form I
9	Form I	Diethyl ether	Dimethyl sulfoxide	-15 to -20	Form I
10	Form I	Dimethyl carbonate	2-Methoxyethanol	65-70	Form I

11	Form I	Heptane	Ethanol + Methanol	0-5	Form I
12	Form I	Methyl tertiary butyl ether	Acetic acid + 1,4-Dioxane	-10 to -15	Form I
13	Form I	Methyl tertiary butyl ether	Dimethyl acetamide	-10 to -15	Form I
14	Form I	n-Heptane	Methanol + 1,4-Dioxane	-15 to -20	Form I
15	Form I	Toluene	Dimethyl sulfoxide	65-70	Form I
16	Form I	Vinyl acetate	2-Methoxyethanol	65-70	Form I
17	Form I	Water	Benzyl alcohol	0-5	Form I
18	Form I	Xylene	Formamide	65-70	Form I

Reactive crystallization

S. No.	Input Form	PTSA (mole eqv.)	Solvent	Antisolvent	Temp. (°C)	Result
1	Niraparib free base	1	1,2 Dichloroethane + Methanol	Heptane	-15 to -20	Form I
2	Niraparib free base	1	1,2 Propanediol	Methyl tertiary butyl ether	50-55	Form I
3	Niraparib free base	1	1,2 Propanediol	Water	0-5	Form I
4	Niraparib free base	1	1,2 Propanediol	Heptane	-15 to -20	Form I
5	Niraparib free base	1	1,4 Dioxane	NA	50-55	Form I
6	Niraparib free base	1	1,4 Dioxane	NA	0-5	Form I
7	Niraparib free base	1	1,4-Dioxane + Ethanol	Heptane	-5 to -10	Form I
8	Niraparib free base	1	2-Hexanone	Heptane	-5 to -10	Form I
9	Niraparib free base	1	Acetone + Acetic acid	NA	25-30	Form I
10	Niraparib free base	1	Acetonitrile + 1,4 Dioxane	Ethanol + Water	25-80	Form I
11	Niraparib free base	1	Anisole + Ethanol	Heptane	-5 to -10	Form I
12	Niraparib free base	1	Ethanol	NA	50-55	Form I
13	Niraparib free base	1	Ethanol	NA	0-5	Form I
14	Niraparib free base	2	Ethanol	Heptane	0-5	Form I
15	Niraparib free base	1.5	Ethanol	NA	0-5	Form I

16	Niraparib free base	1.5	Ethanol	Heptane	0-5	Form I
17	Niraparib free base	1	Ethanol	Heptane	-15 to -20	Form I
18	Niraparib free base	1	Ethanol	n-Hexane	-15 to -20	Form I
19	Niraparib free base	1	Ethanol+1,4-Dioxane	Heptane	-15 to -20	Unstable novel form
20	Niraparib free base	1	Ethanol + Dichloromethane	Heptane	-15 to -20	Form I
21	Niraparib free base	1	Ethyl formate + Ethanol	Heptane	-15 to -20	Form I
22	Niraparib free base	1	Formic acid	Methyl tertiary butyl ether	-5 to -10	Form I
23	Niraparib free base	1	Formic acid + Acetone	Methyl tertiary butyl ether	0-5	Form I
24	Niraparib free base	1	Isopropyl acetate	NA	-15 to -20	Form I
25	Niraparib free base	1	MEK	Heptane	-15 to -20	Form I
26	Niraparib free base	1	Methanol	NA	25-30	Form I
27	Niraparib free base	1	Methanol	NA	60-65	Form I
28	Niraparib free base	2	Methanol	DIPE	0-5	Form I
29	Niraparib free base	1	Methanol	Methyl tertiary butyl ether + Heptane	0-5	Form I
30	Niraparib free base	1	Methanol	n-Hexane	-15 to -20	Form I
31	Niraparib free base	1	Methyl isobutyl ketone	NA	-15 to -20	Form I
32	Niraparib free base	1	Methyl isobutyl ketone	Heptane	-15 to -20	Form I
33	Niraparib free base	0.5	Methyl isobutyl ketone	Heptane	-15 to -20	Form I
34	Niraparib free base	1	Methyl isobutyl ketone	Heptane	25-30	Form I
35	Niraparib free base	1	Methyl isobutyl ketone + Ethanol	Heptane	-15 to -20	Form I
36	Niraparib free base	1	Nitromethane	Heptane	-15 to -20	Form I
37	Niraparib free base	1	Tetrahydrofuran + Acetone	Heptane	-15 to -20	Form I

38	Niraparib free base	1	Trifluoroethanol	Heptane	-15 to -20	Form I
----	---------------------	---	------------------	---------	------------	--------

Table S2: Experimental cocrystal screening details.

Cocrystallization							
S. No.	Input Form	Coformer	Mole eqv.	Solvent	Antisolvent	Temp. (°C)	Result
1	Form I	2,5-Dihydroxy benzoic acid	1	Methanol	NA	25-30	Form I
2	Form I	2,5-Dihydroxy benzoic acid	2	Isopropanol	NA	25-30	PM
3	Form I	2,5-Dihydroxy benzoic acid	1.2	Ethyl acetate	NA	25-30	PM
4	Form I	2,5-Dihydroxy benzoic acid	2	Methanol	NA	50-55	PM
5	Form I	2,5-Dihydroxy benzoic acid	2	Tetrahydrofuran	NA	35-40	PM
6	Form I	2,5-Dihydroxy benzoic acid	1	Acetone	NA	35-40	PM
7	Form I	Benzoic acid	2	2,2,2-Trifluoroethanol	Methyl tertiary butyl ether	25-30	PM
8	Form I	Benzoic acid	2	Ethanol	NA	25-30	Form I
9	Form I	Benzoic acid	2	Ethanol	Ethyl acetate	25-30	PM
10	Form I	Benzoic acid	3	Ethanol	Acetone	25-30	PM
11	Form I	Aspartame	1.2	Isopropanol	NA	35-40	PM
12	Form I	Aspartame	1	Isopropanol	NA	70-75	PM
13	Form I	Aspartame	1	Ethyl acetate	NA	70-75	PM
14	Form I	Aspartame	1	Acetonitrile	NA	70-75	PM
15	Form I	Caffeine	1	Methanol	NA	55-60	Form I
16	Form I	Caffeine	2	Tetrahydrofuran	NA	45-50	Form I
17	Form I	Caffeine	3	Methanol	Methyl tertiary butyl ether	55-60	PM
18	Form I	Citric acid	1	Acetone	NA	25-30	Form I
19	Form I	Citric acid	1.2	Isopropyl acetate	NA	50-55	Form I
20	Form I	Citric acid	1	Tetrahydrofuran	NA	25-30	PM
21	Form I	Citric acid	1	Acetonitrile	NA	-5-0	PM
22	Form I	D-Proline	1	Acetonitrile	NA	70-75	Form I

23	Form I	D-Proline	2	Methanol	Acetonitrile	70-75	Form I
24	Form I	D-Tartaric acid	1	Acetone	NA	25-30	Form I
25	Form I	D-Tartaric acid	2	Methanol	NA	25-30	Form I
26	Form I	D-Tartaric acid	1	Methanol	Methyl tertiary butyl ether	35-40	PM
27	Form I	Fumaric acid	1	Methanol	NA	35-40	Form I
28	Form I	Fumaric acid	2	Methanol	Methyl tertiary butyl ether	35-40	PM
29	Form I	Fumaric acid	2	Isobutanol	NA	35-40	PM
30	Form I	Fumaric acid	2	Ethyl acetate	NA	35-40	PM
31	Form I	Fumaric acid	2	Isopropyl acetate	NA	35-40	PM
32	Form I	L-Histidine	1.2	Methanol + Acetonitrile	NA	60-65	PM
33	Form I	L-Histidine	1.2	Ethanol + Acetonitrile	NA	-15 to -20	Form I
34	Form I	L-Aspartic acid	1.2	Acetonitrile	NA	25-30	PM
35	Form I	L-Aspartic acid	1.2	Methanol + Acetonitrile + water	NA	70-75	Form I
36	Form I	L-Malic acid	3	Methanol	NA	25-30	Form I
37	Form I	L-Malic acid	3	Methanol + Acetone	NA	35-40	Form I
38	Form I	L-Malic acid	3	Isopropanol	NA	50-55	Form I
39	Form I	L-Malic acid	3	Dichloromethane	NA	25-30	Form I
40	Form I	L-Malic acid	3	Methanol	Methyl tertiary butyl ether	35-40	Form I
41	Form I	Methyl paraben	2	2,2,2-Trifluoroethanol	Methyl tertiary butyl ether	25-30	PM
42	Form I	Methyl paraben	2	Ethanol	Ethyl acetate	25-30	PM
43	Form I	Methyl paraben	1	Methanol	Acetonitrile	65-70	PM
44	Form I	Methyl paraben	2	Acetonitrile	NA	70-75	PM
45	Form I	Nicotinamide	2	Ethanol	Ethyl acetate	25-30	PM
46	Form I	Nicotinamide	2	Ethanol	NA	25-30	PM

47	Form I	Nicotinamide	2	Acetonitrile	NA	25-30	Form I
48	Form I	Nicotinamide	1	Methanol	Acetonitrile	70-75	Form I
49	Form I	Nicotinamide	1	Methanol	n-Heptane	65-70	Form I
50	Form I	Nicotinamide	3	Acetonitrile	NA	70-75	Form I
51	Form I	Oxalic acid dihydrate	1	Methanol	NA	25-30	Form I
52	Form I	Oxalic acid dihydrate	1.2	Ethanol	NA	30-35	Form I
53	Form I	Oxalic acid dihydrate	3	Ethanol	NA	-15 to -10	PM
54	Form I	Oxalic acid dihydrate	3	Methanol	n-Butyl acetate	0-5	PM
55	Form I	Succinic acid	1	Methanol	NA	35-40	Form I
56	Form I	Succinic acid	2	Ethanol	NA	35-40	PM
57	Form I	Succinic acid	2	Isopropanol	NA	35-40	PM
58	Form I	Succinic acid	2	2,2,2-Trifluoroethanol + Methyl tertiary butyl ether	NA	25-30	Form I
59	Form I	Succinic acid	1	Methanol + Ethanol	Ethyl acetate	25-30	Form I
60	Form I	Succinic acid	2	Acetonitrile	Acetone	35-40	PM
61	Form I	Maleic acid	1	Methanol	NA	45-50	PM
62	Form I	Maleic acid	3	Methanol	Methyl tertiary butyl ether	35-40	PM
63	Form I	Maleic acid	3	Methanol	1,4-dioxane	20-25	Form I
64	Form I	Maleic acid	1	Methanol	Acetone	45-50	Form I
65	Form I	Maleic acid	1.2	Methanol + Tetrahydrofuran	n-Heptane	25-30	Form I
66	Form I	Maleic acid	1	Dimethyl carbonate	NA	25-30	Form I
67	Form I	Maleic acid	1	Ethyl acetate	NA	25-30	PM
68	Form I	Maleic acid	1	Acetonitrile	NA	25-30	Form I
69	Form I	Maleic acid	2	Acetonitrile	NA	25-30	PM
70	Form I	Maleic acid	2	Dimethyl formamide	Dimethyl carbonate	50-55	Form I
71	Form I	Maleic acid	2	Dimethyl formamide	Methyl tertiary	50-55	Form I

					butyl ether		
72	Form I	Maleic acid	3	Dimethyl sulfoxide	Methyl isobutyl ketone	50-55	PM
73	Form I	Maleic acid	3	Dimethyl sulfoxide	Ethyl acetate	50-55	PM
74	Form I	Maleic acid	3	Dimethyl sulfoxide	Anisole	50-55	PM
75	Form I	Maleic acid	2	Ethanol	NA	25-30	PM
76	Form I	Maleic acid	1.2	Ethanol	Heptane + Methyl tertiary butyl ether	15-20	Form I
77	Form I	Maleic acid	2	Ethanol	Water	0 - 5	Form I
78	Form I	Maleic acid	3	Ethanol	Ethyl acetate	-5 to 0	PM
79	Amorphous	Maleic acid	1.2	Ethanol	NA	25-30	Form I
80	Amorphous	Maleic acid	2	2-ethoxy ethanol	NA	0-5	Form I
81	Amorphous	Maleic acid	2	Acetonitrile	NA	70-75	PM
82	Amorphous	Maleic acid	2	Ethyl acetate + acetone	NA	70-75	PM
83	Amorphous	Maleic acid	1.2	Ethanol + Methanol	Pentane	25-30	PM
84	Amorphous	Maleic acid	2	Ethanol + Tetrahydrofuran + Methanol	Pentane	25-30	PM
85	Niraparib free base	PTSA & Oxalic acid	1 & 2	Ethanol + Acetonitrile	NA	25-30	Form I
86	Niraparib free base	PTSA & Maleic acid	1 & 1	Ethanol	Ethyl acetate	35-40	Form I
87	Niraparib free base	PTSA & D-Tartaric acid	1 & 1	Ethyl acetate + Methanol	NA	25-30	PM
88	Niraparib free base	PTSA & Succinic acid	1 & 1	Ethanol	Ethyl acetate	25-30	Form I
89	Niraparib free base	PTSA & Succinic acid	1 & 2	Acetonitrile + Ethanol	NA	25-30	PM
90	Niraparib free base	PTSA & Fumaric acid	1 & 1	Acetonitrile + Ethanol	NA	35-40	Form I
91	Niraparib free base	PTSA & L-Malic acid	1 & 1	Ethanol	Ethyl acetate	35-40	Form I

92	Form I	L-Proline	1	Methanol	NA	25-30	Form I
93	Form I	L-Proline	1	Acetonitrile	NA	40-45	PM
94	Form I	L-Proline	1	Methanol	Acetonitrile	25-30	PM
95	Form I	L-Proline	1	Methanol	Petroleum ether	0-10	Form III
96	Form I	L-Proline	2	Acetone + Water	NA	45-50	Form I
97	Form I	L-Proline	2	Acetonitrile + Water	NA	70-75	Form I
98	Form I	L-Proline	2	Tetrahydrofuran + Water	NA	45-50	Form I
99	Form I	L-Proline	1.2	Methanol	NA	50-55	PM of Form I & NIR.TO S.PRO
100	Form I	L-Proline	1.2	Methanol	Acetonitrile	50-55	PM of Form I & NIR.TO S.PRO
101	Form I	L-Proline	1.2	2,2,2-Trifluoroethanol	Acetonitrile	70-75	NIR.TO S.PRO
102	Form I	L-Proline	1.2	Methanol	Acetonitrile	70-75	NIR.TO S.PRO
103	Form I	L-Proline	1.2	Acetonitrile	NA	70-75	NIR.TO S.PRO

Note: In the above table, niraparib tosylate monohydrate is mentioned as Form I. PM stands for physical mixture of Form I and respective coformer. NIR.TOS.PRO stands for niraparib tosylate L-proline zwitterionic salt-cocrystal. In few experiments, Form III or physical mixture of Form I and Form III were observed during in-process PXRD analysis, however they eventually converted to the stable Form I after final filtration or drying. The experimental NIR.TOS.PRO hits are highlighted in violet colour.




Figure S4: PXRD pattern of new polymorph in comparison with NIR.TOS.H₂O.




Figure S5: PXRD pattern of new polymorph in comparison with Form II of Niraparib tosylate.




Figure S6: PXRD pattern of new polymorph in comparison with Form III of Niraparib tosylate.




Figure S7: DSC & TGA overlay of new polymorph of Niraparib tosylate.




Figure S8. ORTEP representation of NIR.TOS.H₂O drawn at 50% probability of non-hydrogen atoms. The piperidyl ring in Niraparib has disorder, which is omitted for clarity.




Figure S9. ORTEP representation of NIR.TOS.PRO drawn at 50% probability of non-hydrogen atoms.




Figure S10. Experimental and simulated PXRD patterns of NIR.TOS.PRO with one-to one correspondence.




Figure S11: Powder X-ray diffraction patterns of NIR.TOS.PRO (red pattern) in pH 1.2 (blue), 4.5 (brown) and 6.8 (pink) buffers (characterized with the residue after dissolution experiment). The salt-cocystal is dissociated in all the media and converted to NIR.TOS.H₂O.




Figure S12: Overlay of powder X-ray diffraction patterns of 6-months stored stability samples of NIR.TOS.PRO in comparison with the input.

Table S3: Torsion angles that are majorly deviated in NIR.TOS.H₂O and NIR.TOS.PRO.

Considered consecutive atoms	NIR.TOS.H ₂ O	NIR.TOS.PRO
C12-C15-C16-N4 (τ_1)	177.16°	-171.03°
C12-C15-C19-C18 (τ_2)	52.45°	175.96°

Table S4: Hydrogen bond parameters of NIR.TOS.H₂O and NIR.TOS.PRO.

Interaction	D-H/Å	H...A/Å	D...A/Å	\angle D-H...A/°	Symmetry code
NIR.TOS.H₂O					
N4B-H4BA...O1	0.92	2.13	2.98(9)	152	1-x, 2-y, 1-z
N1-H1A...O4	0.84(11)	2.22(11)	2.93(7)	143(10)	1-x, 2-y, 1-z
N4B-H4BB...O5	0.92	2.06	2.95(9)	162	1-x, 2-y, 1-z
N4A-H4AA...O5	0.92	1.88	2.75(9)	158	1-x, 2-y, 1-z
N4A-H4AB...O5	0.92	1.91	2.83(9)	175	x, y, z
O5-H5A...N4A	0.85	2.12	2.75(9)	131	1+x, y, z
O5-H5B...O3	0.85	1.93	2.76(5)	163	x, y, z
C16A-H16D...O2	0.99	2.60	3.57(18)	168	x, y, z
C17-H17D...O1	0.99	2.40	3.27(9)	146	1-x, 2-y, 1-z
NIR.TOS.PRO					
N1-H1A...O6	0.83(3)	2.05(3)	2.87(3)	174(3)	1-x, -1/2+y, 2-z
N4-H4A...O1	0.92	1.88	2.69(3)	145	1-x, -1/2+y, 1-z
N4-H4B...O5	0.92	1.87	2.78(3)	166	x, y, z
N5-H5A...O4	0.92	1.80	2.70(3)	167	x, y, z
C8-H8...O3	0.95	2.55	3.50(3)	177	1-x, -1/2+y, 1-z
C26-H26C...O6	0.98	2.57	3.53(4)	165	2-x, -1/2+y, 1-z